| Literature DB >> 34430935 |
Yumi Ishii1, Ichitaro Abe1, Shintaro Kira1, Taisuke Harada1, Masayuki Takano1, Takahiro Oniki1, Hidekazu Kondo1, Yasushi Teshima1, Kunio Yufu1, Takashi Shuto2, Tomoyuki Wada2, Mikiko Nakagawa3, Tatsuo Shimada4, Yoshiki Asayama5, Shinji Miyamoto2, Naohiko Takahashi1.
Abstract
BACKGROUND: Fibrotic remodeling of epicardial adipose tissue (EAT) is crucial for proinflammatory atrial myocardial fibrosis, which leads to atrial fibrillation (AF).Entities:
Keywords: Atrial fibrillation; Computed tomography; Epicardial adipose tissue; Fat attenuation; Fibrosis; Inflammation
Year: 2021 PMID: 34430935 PMCID: PMC8369308 DOI: 10.1016/j.hroo.2021.05.006
Source DB: PubMed Journal: Heart Rhythm O2 ISSN: 2666-5018
Figure 1Definition of 2 types of epicardial adipose tissue (EAT). Central EAT (C-EAT) was defined as the central area of EAT that is not attached to either the myocardium or epicardium (orange area). Marginal EAT (M-EAT) was defined as the area within 150 μm from the myocardium, including the adipocytes in contact with the myocardium (green area).
Patient characteristics
| All patients (n = 76) | Paroxysmal AF (n = 28) | Persistent AF (n = 48) | ||
|---|---|---|---|---|
| Age (years) | 71.9 ± 8.2 | 69.9 ± 10.2 | 73.2 ± 6.7 | .09 |
| Sex | ||||
| Male | 40 (53) | 12 (43) | 28 (58) | .19 |
| Female | 36 (47) | 16 (57) | 20 (42) | .19 |
| BMI (kg/m2) | 23.2 ± 3.6 | 22.6 ± 2.7 | 23.6 ± 4.0 | .24 |
| History of present and past illness | ||||
| Hypertension | 39 (51) | 14 (50) | 25 (52) | .86 |
| Diabetes mellitus | 18 (24) | 4 (14) | 14 (29) | .14 |
| Dyslipidemia | 30 (39) | 12 (43) | 18 (38) | .64 |
| Coronary artery disease | 17 (22) | 7 (25) | 10 (21) | .67 |
| Cerebral infarction | 14 (18) | 6 (21) | 8 (17) | .61 |
| Sleep apnea | 1 (1) | 0 (0) | 1 (1) | .44 |
| Smoking | 28 (37) | 11 (39) | 17 (35) | .74 |
| Alcohol use | 22 (29) | 4 (14) | 18 (38) | <.05 |
| CHADS2 score | 2.6 ± 1.1 | 2.5 ± 1.1 | 2.6 ± 1.1 | .50 |
| CHA2DS2-VASc score | 4.0 ± 1.4 | 4.0 ± 1.3 | 4.1 ± 1.5 | .85 |
| Surgical procedure | ||||
| Valve replacement/repair | 51 (67) | 21 (75) | 30 (63) | .26 |
| Aorta replacement | 6 (8) | 0 (0) | 6 (13) | .05 |
| CABG | 1 (1) | 0 (0) | 1 (2) | .44 |
| Combined (CABG and valve) | 14 (18) | 7 (25) | 7 (15) | .26 |
| Combined (aorta and valve) | 3 (4) | 0 (0) | 3 (6) | .17 |
| Combined (ASD closure and valve) | 1 (1) | 0 (0) | 1 (2) | .44 |
| BUN (mg/dL) | 25 ± 13 | 23 ± 14 | 25 ± 12 | .39 |
| Cr (mg/dL) | 1.4 ± 1.8 | 1.8 ± 2.8 | 1.2 ± 0.6 | .13 |
| BNP (pg/mL) | 358 ± 435 | 430 ± 500 | 311 ± 388 | .31 |
| eGFR (mL/min/1.73 m2) | 51 ± 20 | 53 ± 22 | 50 ± 19 | .45 |
| LAD (mm) | 52 ± 10 | 47 ± 8 | 54 ± 11 | <.01 |
| LVDd (mm) | 53 ± 9 | 52 ± 9 | 53 ± 9 | .45 |
| EF (%) | 59 ± 12 | 62 ± 13 | 58 ± 13 | .13 |
| E/e' | 22 ± 13 | 25 ± 13 | 20 ± 12 | .11 |
| AR II°-III° | 19 (25) | 5 (18) | 14 (29) | .27 |
| AS moderate-severe | 18 (24) | 8 (29) | 10 (21) | .44 |
| MR II°-III° | 47 (62) | 17 (61) | 30 (63) | .88 |
| MS moderate-severe | 11 (14) | 6 (21) | 5 (10) | .19 |
| EAT volume (mL) | 89 ± 46 | 71 ± 28 | 99 ± 51 | <.05 |
| EAT volume corrected by BMI | 3.8 ± 1.6 | 3.1 ± 1.1 | 4.1 ± 1.8 | <.01 |
Data are given as mean ± SD or n (%).
AF = atrial fibrillation; AR = aortic regurgitation; AS = aortic stenosis; ASD = atrial septal defect; BMI = body mass index; BNP = brain natriuretic peptide; BUN = blood urea nitrogen; CABG = coronary artery bypass graft; Cr = creatinine; E/e = the ratio of the peak early mitral inflow velocity (E) over the early diastolic mitral annular velocity (e′); EAT = epicardial adipose tissue; EF = ejection fraction; eGFR = estimated glomerular filtration rate; LAD = left atrial diameter; LVDd = left ventricular end-diastolic diameter; MR = mitral regurgitation; MS = mitral stenosis.
Figure 2Fibrotic remodeling of epicardial adipose tissue (EAT) and adipocyte diameter. A: (a) Representative photomicrograph of excised left atrial appendage, and (b)(c) sections with Masson’s trichrome staining. B: Representative photomicrographs of (a) immunostaining for α-SMA (red arrows), (b) transmission electron microscope imaging, (c) immunostaining for CD68 (yellow arrows) and CD3 (silver arrows). CD68, green; CD3, red and DAPI, blue. (d)–(f) Corresponding quantitative analysis of (a)–(c). C: (a) Representative cases and (b)(c) corresponding quantitative analysis. C-EAT = central EAT; Endo = endocardium; Epi = epicardium; M-EAT = marginal EAT.
Figure 3Relationship of adipocyte diameter with body mass index (BMI) and epicardial adipose tissue (EAT) volume. A: (a)(b) Representative examples; B: (a)(b) correlation of adipocyte diameter with BMI and EAT volume. C-EAT = central EAT; M-EAT = marginal EAT.
Figure 4Microarray analyses and effects of cytokines on expression levels of adipogenesis-related mRNAs. A: (a)–(c) Downregulation (green) and upregulation (yellow) of inflammation-, fibrosis-, and adipogenesis-related genes in central epicardial adipose tissue (C-EAT) compared with marginal EAT (M-EAT). B: (a)–(h) Gene expression related to adipogenesis in EAT treated with IL-6 (25 ng/mL), TGF-β1 (1 ng/mL), and TNF-α (5 ng/mL).
Figure 5Central-to-marginal (C/M) ratio of adipocyte diameter. A: (a)(b) Representative examples. B: Correlation of epicardial adipose tissue (EAT) fibrosis with (a)(b) adipocyte diameter and (c) C/M diameter ratio (ratio of adipocyte diameter in central EAT [C-EAT] to that in marginal EAT [M-EAT]).
Figure 6Central-to-marginal (C/M) diameter ratio and myocardial fibrosis. A: (a)(b) Representative cases. B: Correlation of C/M diameter ratio with (a) myocardial fibrosis and (b) total collagen in myocardium. (c) Myocardial fibrosis, (d) total collagen in myocardium, and C: C/M diameter ratio were higher in patients with persistent atrial fibrillation (PeAF) than paroxysmal atrial fibrillation (PAF).
Figure 7The percent change (%change) in epicardial adipose tissue (EAT) fat attenuation by computed tomography imaging. A: Representative heat map of EAT fat attenuation in mild (a) and severe fibrotic remodeling of EAT cases (b). B: Correlation between the %change in EAT fat attenuation and the EAT fibrosis. C: Comparison of the %change in EAT fat attenuation between paroxysmal atrial fibrillation (PAF) and persistent atrial fibrillation (PeAF). D: Correlation between the %change in EAT fat attenuation and the central-to-marginal (C/M) diameter ratio.